2 Strategic Trends Driving APAC

In the Asia-Pacific region, we see two key strategic trends within Policy, Access, Value, and Evidence:

1. Continuing and increased use of Health Technology Assessment (HTA) in public payer decisions with increasing convergence of policies and processes

2. The impact of China is being felt in two ways:

i. In the market, National Reimbursement Drug List (NRDL) decisions driving strategic options for companies, impacting pricing, access models, and even launch go/no go decisions

ii. In global markets, the increasing presence of Chinese biotechs launching products in the US and Europe.

1. Continuing and increased use of HTA in public payer decisions with increasing convergence of policies and processes

This is especially within mature markets such as Australia, New Zealand, Japan, Korea, and Taiwan, but also in some newer markets as well - China and most of Southeast Asia, including Thailand, Indonesia, the Philippines, Malaysia, Vietnam, and India.

The mature Asia-Pacific markets, in many respects, have systems and levels of economic development and patient expectations that are similar to those in Europe. They also have universal healthcare systems and national, government-led reimbursement. The expectations and requirements of governments in these developed markets is around getting the best technologies and the best outcomes for what they’re spending. In other words, “How do we get the best value?”. These markets are also more focused on ageing populations, and treatments for cancer and chronic diseases; people here also expect high-quality care, so anything less than that would be unacceptable and may well become an issue at election time.